1 Min Read
Feb 28 (Reuters) - Antisense Therapeutics Ltd:
* APPROVAL RECEIVED FOR PHASE II TRIAL OF ATL1102 IN DUCHENNE MUSCULAR DYSTROPHY Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.